top of page

Program 

Wednesday 3rd May, 2023

08:00-09:00

Registration, Gathering and Exhibition

09:00-11:15

Session 1

Chairpersons: Dr. Ofir Wolach & Dr. Itai Levi

09:00-09:30 - Opening Remarks

09:30-10:05- Non-Ph+ ALL
                      Hagop Kantarjian, MD, MD Anderson, Houston, USA

10:05-10:40 - Are we ready for risk-adapted therapy in CML 

                    Timothy Hughes, MD, SAHMRI Beat Cancer, University of Adelaide, Australia

10:40-11:15 - Novel prediction models in cancer associated thrombosis

                      Jeffrey I. Zwicker, MD,Memorial Sloan Kettering Cancer Center, NY, USA

videocamera-icon-png-and-vector-for-free-download-449572.png

Coffee Break

11:15-11:45

Session 2

11:45-13:30

Chairpersons: Dr. Avi Leader & Dr. Tamar Tadmor

11:45-12:20 - Personalized induction strategies for AML

                       Gail J. Roboz, MD, Weill Cornell Medicine, The New York Presbyterian                                 Hospital, New York, USA

12:20-12:55 - Updates in T cell lymphoma with focus on emerging cellular therapies
                       Swaminathan Padmanabhan Iyer, MD, MD Anderson, Houston, USA

12:55-13:30 - Present and future of molecular testing in CML

                      Simona Soverini, Ph.D, Alma Mater Studiorum Universita di Bologna, Italy

videocamera-icon-png-and-vector-for-free-download-449572.png

13:30-14:45

Lunch Break & Guided museum tour

14:45-17:05

Session 3

Chairpersons: Dr. Anat Gafter- Gvili & Dr. Luliana Vaxman

14:45-15:20 - Acute lymphoblastic leukemia at a single base resolution

                     Gidi Rechavi, MD, Sheba Cancer Research Center, Tel-Hashomer, Israel

15:20-15:55 - Moving towards personalized therapy for Hodgkin lymphoma

                       Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY,USA

15:55-16:30 - When not to transplant in ALL?

                       Elias Joseph Jabbour, MD, MD Anderson, Houston, USA

16:30-17:05 - Should high risk smoldering myeloma be treated outside of a clinical trial?

                       Morie Gertz, MD, Mayo Clinic, Rochester Minnesota, USA

videocamera-icon-png-and-vector-for-free-download-449572.png
videocamera-icon-png-and-vector-for-free-download-449572.png

17:05-17:15

Closing Remarks

Thursday 4th May, 2023

08:15-09:00

Registration, Gathering and Exhibition

09:15-11:00

Session 4

Chairperson: Dr. Tzila Zuckerman & Dr. Avichai Shimoni

09:00-09:15 - Opening Remarks

09:15-09:50 - HMA/VEN...and then?

                     Richard Stone, MD, Dana Farber, Boston, USA

09:50-10:25 - Dormancy as a mechanism of innate resistance to therapy in myeloid malignancies                             Michael Deininger, MD, Versiti, USA

10:25-11:00 - Ph+ ALL today

                     Robin Foa, MD, "Sapienza" University of Rome, Italy

videocamera-icon-png-and-vector-for-free-download-449572.png

11:00-11:30

Coffee Break

11:30-13:15

Session 5

Chairpersons: Dr. Merav Leiba & Dr. Nadav Sarid

11:30-12:05 - From broad to ultra targeted therapeutic approaches in CML: which one is                                best?

                        Delphine Rea, MD, Hôpital Saint Louis, Paris, France

12:05-12:40 - CML treatment discontinuation in clinical practice: how can we ameliorate its                                       feasibility?

                       Giuseppe Saglio, MD, University of Turin, Italy

12:40-13:15- Lymphoma/cellular therapy

                      Loretta Nastoupil, MD, MD Anderson, Houston, USA

13:30-14:45

Lunch Break & Guided museum tour

videocamera-icon-png-and-vector-for-free-download-449572.png
videocamera-icon-png-and-vector-for-free-download-449572.png

14:30-17:20

Session 6

Chairpersons: Dr. Moshe Gatt & Dr. Ariel Aviv

14:30-15:05 - Anticoagulant-related bleeding in Cancer

                      Kristen Sanfilippo, MD, Washington University School of Medicine in St. Louis,USA

15:05-15:40 - T-cell lymphoma

                      Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center NY, USA

15:40-16:15 - Advances and remaining challenges for patients with Follicular Lymphoma

                      Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA

16:15-17:20 - Novel agents in CLL: better sequenced or combined

                      Jan Burger, MD, MD Anderson, Houston, USA

videocamera-icon-png-and-vector-for-free-download-449572.png
videocamera-icon-png-and-vector-for-free-download-449572.png

17:20-17:30

Closing Remarks

Friday 5th May, 2023

09:00-12:00- Round Table Symposiums

09:00-10:00- CLL and Plasma Cell Dyscrasias

Participants:

  1. Jan Burger, MD, Houston, USA

  2. Morie Gertz, MD, Rochester, USA

  3. Tamar Tadmor, MD, Haifa, Israel

  4. Iuliana Vaxman, MD, Petah-Tikva, Israel

  5. Gilad Itchaki, MD, Petah-Tikva, Israel \ 

 

10:00--11:00- Chronic Myeloid Leukemia

Participants:

  1. Simona Soverini, Ph.D, Bologna, Italy

  2. Giuseppe Saglio, MD, Turin, Italy

  3. Pia Raanani, MD, Petah- Tikva, Israel

  4. Mr. Giora Sharf, Expert Patient Advocate, Israel

 

11:00-12:00- Acute Leukemia

Participants:

  1. Hagop Kantarjian, MD, Houston, USA

  2. Gail Roboz, MD, New York, USA

  3. Richard Stone, MD, Boston, USA

  4. Robin Foa, MD, Rome, Italy

  5. Ofir Wolach, MD, Petah-Tikva, Israel

bottom of page